Our analysis of two clinical cohorts showed that SNAP‐25 could differentiate between patients with AD and the non‐neurodegenerative diseases NPH and VaD but lacked the ability to differentiate between the AD and non‐AD neurodegenerative diseases. Here, SNAP25 is linked to normal pressure hydrocephalus.